283 related articles for article (PubMed ID: 35887860)
1. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis.
Jeridi D; Pellat A; Ginestet C; Assaf A; Hallit R; Corre F; Coriat R
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887860
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis.
Luo X; Hou M; He S; Yang X; Zhang P; Zhao Y; Xing H
Front Pharmacol; 2022; 13():1021584. PubMed ID: 36703730
[No Abstract] [Full Text] [Related]
5. Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel.
Li S; Liu F; Chen C; Zhu W; Ma J; Hu J; Xu J; Hong K
Int Heart J; 2019 Jul; 60(4):910-918. PubMed ID: 31308328
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis.
Pang J; Wu Q; Zhang Z; Zheng TZ; Xiang Q; Zhang P; Liu X; Zhang C; Tan H; Huang J; Liu W; Song F; Tan H; Li Z; Yue F; Jiang Z; Wei F; Zhou K; Tang F; Yang Y; Long X; Kuang C; Wu Y; Chen B; Tian Y
Int J Cardiol Heart Vasc; 2019 Jun; 23():100317. PubMed ID: 31321282
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
Serbin MA; Guzauskas GF; Veenstra DL
J Manag Care Spec Pharm; 2016 Aug; 22(8):939-47. PubMed ID: 27459657
[TBL] [Abstract][Full Text] [Related]
8. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
[No Abstract] [Full Text] [Related]
9. Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis.
Guo H; Ye Z; Huang R
Front Pharmacol; 2021; 12():694698. PubMed ID: 34408652
[No Abstract] [Full Text] [Related]
10. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.
Kwok CS; Jeevanantham V; Dawn B; Loke YK
Int J Cardiol; 2013 Aug; 167(3):965-74. PubMed ID: 22464478
[TBL] [Abstract][Full Text] [Related]
11. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.
Kwok CS; Nijjar RS; Loke YK
Drug Saf; 2011 Jan; 34(1):47-57. PubMed ID: 21047145
[TBL] [Abstract][Full Text] [Related]
12. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention.
Lee D; Kim JS; Kim BJ; Shin SY; Kim DB; Ahn HS
Medicine (Baltimore); 2021 Dec; 100(52):e27411. PubMed ID: 34967346
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and potential interactions with clopidogrel: an update.
Gerson LB
Curr Gastroenterol Rep; 2013 Jun; 15(6):329. PubMed ID: 23695547
[TBL] [Abstract][Full Text] [Related]
14. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
[TBL] [Abstract][Full Text] [Related]
15. PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis.
Demcsák A; Lantos T; Bálint ER; Hartmann P; Vincze Á; Bajor J; Czopf L; Alizadeh H; Gyöngyi Z; Márta K; Mikó A; Szakács Z; Pécsi D; Hegyi P; Szabó IL
Front Physiol; 2018; 9():1550. PubMed ID: 30510515
[No Abstract] [Full Text] [Related]
16. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis.
Niu Q; Wang Z; Zhang Y; Wang J; Zhang P; Wang C; Yin X; Hou Y
J Cardiovasc Pharmacol Ther; 2017 Mar; 22(2):142-152. PubMed ID: 27512080
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
